CorMedix (CRMD) Shares Up 21%

CorMedix Inc. (NYSEAMERICAN:CRMD)’s share price shot up 21% during mid-day trading on Friday . The company traded as high as $1.32 and last traded at $1.27. 5,514,200 shares were traded during trading, an increase of 100% from the average session volume of 2,762,720 shares. The stock had previously closed at $1.05.

Several equities research analysts recently weighed in on the company. Zacks Investment Research downgraded CorMedix from a “hold” rating to a “sell” rating in a report on Monday, October 1st. HC Wainwright set a $3.00 price target on CorMedix and gave the stock a “buy” rating in a report on Wednesday, August 15th.

CorMedix (NYSEAMERICAN:CRMD) last released its quarterly earnings results on Tuesday, August 14th. The biotechnology company reported ($0.10) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.10). The firm had revenue of $0.01 million for the quarter, compared to analyst estimates of $0.10 million.

CorMedix Company Profile (NYSEAMERICAN:CRMD)

CorMedix, Inc, a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States and internationally. Its primary focus is on the development of its lead product candidate, Neutrolin, an anti-infective solution for the reduction and prevention of catheter-related infections and thrombosis in patients requiring central venous catheters in clinical settings, such as dialysis, critical/intensive care, and oncology.

See Also: Index Funds

Receive News & Ratings for CorMedix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CorMedix and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply